PDL BIOPHARMA, INC. - FORM 8-K - EX-99.2 - INFORMATION SHEET - December 10, 2013

Attached files

file filename
8-K - 8-K - PDL BIOPHARMA, INC.pdli-20131210x8xkdoc.htm
EX-99.1 - PRESS RELEASE - PDL BIOPHARMA, INC.pdli-20131210x8xkex991.htm


Exhibit 99.2

Royalty Revenue by Product ($ in 000's) *
Avastin
Q1
Q2
Q3
Q4
Total
2013
33,234

46,720

32,224

32,287

144,464

2012
23,215

41,670

25,955

30,041

120,882

2011
22,283

41,967

23,870

22,886

111,006

2010
16,870

44,765

29,989

24,922

116,547

2009
13,605

35,161

21,060

15,141

84,966

2008
9,957

30,480

19,574

12,394

72,405

2007
8,990

21,842

17,478

9,549

57,859

2006
10,438

15,572

15,405

12,536

53,952

Herceptin
Q1
Q2
Q3
Q4
Total
2013
30,287

47,353

30,961

33,038

141,640

2012
25,702

44,628

30,433

28,307

129,070

2011
25,089

42,209

31,933

21,812

121,042

2010
23,402

38,555

27,952

25,441

115,350

2009
16,003

32,331

26,830

18,615

93,779

2008
14,092

34,383

28,122

20,282

96,880

2007
19,035

28,188

22,582

14,802

84,608

2006
15,142

19,716

21,557

20,354

76,769

Lucentis
Q1
Q2
Q3
Q4
Total
2013
12,032

30,066

13,536

12,127

67,760

2012
10,791

27,938

12,552

11,097

62,377

2011
8,878

24,313

12,157

10,750

56,099

2010
7,220

19,091

10,841

8,047

45,198

2009
4,621

12,863

8,123

6,152

31,759

2008
3,636

11,060

7,631

4,549

26,876

2007
2,931

6,543

6,579

3,517

19,570

2006
—

—

289

3,335

3,624

Xolair
Q1
Q2
Q3
Q4
Total
2013
5,930

10,025

7,334

7,330

30,619

2012
5,447

8,609

6,504

6,145

26,705

2011
4,590

7,621

5,916

5,823

23,949

2010
3,723

6,386

4,980

4,652

19,741

2009
2,665

5,082

4,085

3,722

15,553

2008
1,488

4,866

3,569

2,927

12,850

2007
1,684

3,942

3,332

2,184

11,142

2006
2,263

2,969

3,041

2,495

10,768

Perjeta
Q1
Q2
Q3
Q4
Total
2013
340

1,414

748

879

3,381

2012
—

—

58

250

308

2011
—

—

—

—

—

2010
—

—

—

—

—

2009
—

—

—

—

—

2008
—

—

—

—

—

2007
—

—

—

—

—

2006
—

—

—

—

—

Kadcyla
Q1
Q2
Q3
Q4
Total
2013
—

551

830

859

2,240

2012
—

—

—

—

—

2011
—

—

—

—

—

2010
—

—

—

—

—

2009
—

—

—

—

—

2008
—

—

—

—

—

2007
—

—

—

—

—

2006
—

—

—

—

—

Tysabri
Q1
Q2
Q3
Q4
Total
2013
12,965

13,616

11,622

12,100

50,304

2012
11,233

12,202

11,749

12,255

47,439

2011
9,891

10,796

11,588

11,450

43,725

2010
8,791

8,788

8,735

9,440

35,754

2009
6,656

7,050

7,642

8,564

29,912

2008
3,883

5,042

5,949

6,992

21,866

2007
839

1,611

2,084

2,836

7,370

2006
—

—

—

237

237

Actemra
Q1
Q2
Q3
Q4
Total
2013
2,631

2,816

2,939

3,744

12,131

2012
1,705

2,074

2,145

2,462

8,385

2011
913

1,136

1,401

1,460

4,910

2010
1,587

237

315

688

2,827

2009
585

537

909

1,197

3,228

2008
44

—

146

369

559

2007
32

—

—

17

49

2006
—

—

—

—

—

* As reported to PDL by its licensees
 
 
    Totals may not sum due to rounding
 
 




Reported Net Sales Revenue by Product ($ in 000's) *
Avastin
Q1
Q2
Q3
Q4
Total
2013
1,653,108

1,694,678

1,746,135

1,819,877

6,913,798

2012
1,502,757

1,573,727

1,551,327

1,662,977

6,290,788

2011
1,597,461

1,582,705

1,581,095

1,469,994

6,231,255

2010
1,506,788

1,596,892

1,594,707

1,646,218

6,344,605

2009
1,345,487

1,295,536

1,439,730

1,514,053

5,594,806

2008
980,715

1,084,930

1,180,427

1,239,382

4,485,454

2007
678,068

746,587

797,013

875,084

3,096,752

2006
439,318

516,052

570,551

592,897

2,118,817

Herceptin
Q1
Q2
Q3
Q4
Total
2013
1,681,574

1,744,145

1,681,860

1,726,551

6,834,130

2012
1,515,255

1,625,313

1,663,695

1,650,495

6,454,759

2011
1,391,568

1,559,975

1,642,898

1,432,771

6,027,211

2010
1,270,846

1,349,512

1,300,934

1,409,310

5,330,602

2009
1,210,268

1,133,993

1,226,435

1,278,626

4,849,323

2008
1,105,426

1,195,215

1,211,982

1,186,806

4,699,428

2007
891,761

949,556

979,602

1,015,033

3,835,952

2006
529,585

659,719

761,099

803,576

2,753,979

Lucentis
Q1
Q2
Q3
Q4
Total
2013
1,203,179

1,171,423

1,200,791

1,212,651

4,788,045

2012
1,079,092

1,086,543

1,097,541

1,109,695

4,372,871

2011
887,757

943,418

1,052,809

1,075,015

3,958,999

2010
721,967

698,890

745,376

804,684

2,970,917

2009
462,103

469,736

555,296

615,212

2,102,347

2008
363,615

393,682

460,167

454,922

1,672,386

2007
224,820

219,579

299,995

322,300

1,066,695

2006
—

—

10,689

157,742

168,431

Xolair
Q1
Q2
Q3
Q4
Total
2013
341,309

365,778

391,900

401,333

1,500,321

2012
310,234

314,638

347,796

340,431

1,313,100

2011
267,754

277,642

310,874

314,911

1,171,182

2010
228,859

225,878

251,055

263,389

969,179

2009
184,669

181,086

211,006

219,693

796,454

2008
137,875

169,521

177,179

183,753

668,329

2007
129,172

130,700

144,250

147,754

551,876

2006
95,241

99,354

112,608

118,002

425,204

Perjeta
Q1
Q2
Q3
Q4
Total
2013
34,008

55,076

66,353

87,949

243,386

2012
—

—

5,080

25,000

30,079

2011
—

—

—

—

—

2010
—

—

—

—

—

2009
—

—

—

—

—

2008
—

—

—

—

—

2007
—

—

—

—

—

2006
—

—

—

—

—

Kadcyla
Q1
Q2
Q3
Q4
Total
2013
—

21,459

73,626

85,906

180,991

2012
—

—

—

—

—

2011
—

—

—

—

—

2010
—

—

—

—

—

2009
—

—

—

—

—

2008
—

—

—

—

—

2007
—

—

—

—

—

2006
—

—

—

—

—

Tysabri
Q1
Q2
Q3
Q4
Total
2013
434,677

451,358

387,407

403,334

1,676,776

2012
374,430

401,743

391,623

408,711

1,576,508

2011
329,696

356,876

388,758

381,618

1,456,948

2010
293,047

287,925

293,664

316,657

1,191,292

2009
221,854

229,993

257,240

285,481

994,569

2008
129,430

163,076

200,783

233,070

726,359

2007
30,468

48,715

71,972

94,521

245,675

2006
—

—

—

7,890

7,890

Actemra
Q1
Q2
Q3
Q4
Total
2013
87,703

91,374

97,961

124,815

401,852

2012
56,662

66,624

71,505

82,053

276,843

2011
30,433

35,370

46,709

48,671

161,183

2010
52,908

5,405

10,493

22,919

91,725

2009
19,504

17,920

30,313

39,888

107,625

2008
1,452

1,377

5,981

12,305

21,115

2007
—

—

—

1,137

1,137

2006
—

—

—

—

—

* As reported to PDL by its licensee. Dates in above charts
 
   reflect when PDL receives royalties on sales. Sales occurred
   in the quarter prior to the dates in the above charts.
 
   Totals may not sum due to rounding
 
 




Manufacturing Location & Sales - Genentech / Roche & Novartis ($ in 000's) *
 
 
 
 
 
 
 
 
 
 
Avastin Sales
2012 - Q3
2012 - Q4
2013 - Q1
2013 - Q2
2013 - Q3
2013 - Q4
US Made & Sold
679,914

710,501

664,109

750,491

716,337

765,636

US Made & ex-US Sold
428,976

281,905

161,369

165,651

360,177

349,836

ex-US Made & Sold
442,437

670,572

827,629

778,536

669,621

704,405

Total
1,551,327

1,662,977

1,653,108

1,694,678

1,746,135

1,819,877

US Made & Sold
44
%
43
%
40
%
44
%
41
%
42
%
US Made & ex-US Sold
28
%
17
%
10
%
10
%
21
%
19
%
ex-US Made & Sold
29
%
40
%
50
%
46
%
38
%
39
%
 
 
 
 
 
 
 
Herceptin Sales
2012 - Q3
2012 - Q4
2013 - Q1
2013 - Q2
2013 - Q3
2013 - Q4
US Made & Sold
503,612

515,790

514,113

583,677

518,790

561,990

US Made & ex-US Sold
545,625

552,127

486,400

563,243

522,159

383,439

ex-US Made & Sold
614,459

582,578

681,060

597,225

640,911

781,123

Total
1,663,695

1,650,495

1,681,574

1,744,145

1,681,860

1,726,551

US Made & Sold
30
%
31
%
31
%
33
%
31
%
33
%
US Made & ex-US Sold
33
%
33
%
29
%
32
%
31
%
22
%
ex-US Made & Sold
37
%
35
%
41
%
34
%
38
%
45
%
 
 
 
 
 
 
 
Lucentis Sales
2012 - Q3
2012 - Q4
2013 - Q1
2013 - Q2
2013 - Q3
2013 - Q4
US Made & Sold
385,746

381,592

392,207

419,030

449,834

461,380

US Made & ex-US Sold
711,795

728,103

810,972

752,393

750,958

751,271

ex-US Made & Sold
—

—

—

—

—

—

Total
1,097,541

1,109,695

1,203,179

1,171,423

1,200,791

1,212,651

US Made & Sold
35
%
34
%
33
%
36
%
37
%
38
%
US Made & ex-US Sold
65
%
66
%
67
%
64
%
63
%
62
%
ex-US Made & Sold
0
%
0
%
0
%
0
%
0
%
0
%
 
 
 
 
 
 
 
Xolair Sales
2012 - Q3
2012 - Q4
2013 - Q1
2013 - Q2
2013 - Q3
2013 - Q4
US Made & Sold
211,702

210,892

207,976

218,860

236,180

242,991

US Made & ex-US Sold
—

—

—

—

—

—

ex-US Made & Sold
136,094

129,540

133,333

146,918

155,720

158,342

Total
347,796

340,431

341,309

365,778

391,900

401,333

US Made & Sold
61
%
62
%
61
%
60
%
60
%
61
%
US Made & ex-US Sold
0
%
0
%
0
%
0
%
0
%
0
%
ex-US Made & Sold
39
%
38
%
39
%
40
%
40
%
39
%
 
 
 
 
 
 
 
Perjeta Sales
2012 - Q3
2012 - Q4
2013 - Q1
2013 - Q2
2013 - Q3
2013 - Q4
US Made & Sold
5,080

24,571

32,377

48,979

49,111

54,168

US Made & ex-US Sold
—

428

1,632

6,096

17,242

33,781

ex-US Made & Sold
—

—

—

—

—

—

Total
5,080

25,000

34,008

55,076

66,353

87,949

US Made & Sold
100
%
98
%
95
%
89
%
74
%
62
%
US Made & ex-US Sold
0
%
2
%
5
%
11
%
26
%
38
%
ex-US Made & Sold
0
%
0
%
0
%
0
%
0
%
0
%
 
 
 
 
 
 
 
Kadcyla Sales
2012 - Q3
2012 - Q4
2013 - Q1
2013 - Q2
2013 - Q3
2013 - Q4
US Made & Sold
—

—

—

21,459

72,887

82,395

US Made & ex-US Sold
—

—

—

—

739

3,510

ex-US Made & Sold
—

—

—

—

—

—

Total
—

—

—

21,459

73,626

85,906

US Made & Sold
0
%
0
%
0
%
100
%
99
%
96
%
US Made & ex-US Sold
0
%
0
%
0
%
0
%
1
%
4
%
ex-US Made & Sold
0
%
0
%
0
%
0
%
0
%
0
%
 
 
 
 
 
 
 
Total Sales
2012 - Q3
2012 - Q4
2013 - Q1
2013 - Q2
2013 - Q3
2013 - Q4
US Made & Sold
1,786,053

1,843,345

1,810,783

2,042,496

2,043,139

2,168,559

US Made & ex-US Sold
1,686,395

1,562,564

1,460,373

1,487,383

1,651,276

1,521,837

ex-US Made & Sold
1,192,990

1,382,690

1,642,023

1,522,679

1,466,252

1,643,870

Total
4,665,438

4,788,598

4,913,178

5,052,559

5,160,667

5,334,267

US Made & Sold
38
%
38
%
37
%
40
%
40
%
41
%
US Made & ex-US Sold
36
%
33
%
30
%
29
%
32
%
29
%
ex-US Made & Sold
26
%
29
%
33
%
30
%
28
%
31
%
* As reported to PDL by its licensee. Dates in above charts
 
 
 
 
   reflect when PDL receives royalties on sales. Sales occurred
 
 
 
 
   in the quarter prior to the dates in the above charts.
 
 
 
 
   Totals may not sum due to rounding
 
 
 
 
 



PDL BIOPHARMA, INC. Reports